Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatic arterial infusion of gemcitabine + oxaliplatin for second-line unresectable intrahepatic cholangiocarcinoma
2017-002330-23Phase 2Active
- Sponsor
- CHU Montpellier
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and oxaliplatin in cholangiocarcinoma (CCA), sponsored by CHU Montpellier. Primary endpoint: Objective response rate at 4 months by RECIST 1.1. Started Oct 2017; status: active.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2017-002330-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002330-23.